Study guide
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape
Key Takeaways Explain This Topic AI
Average THC concentration in illicit cannabis flower has risen from under 4 percent in the 1990s to roughly 15 to 20 percent, and concentrates commonly exceed 60 to 90 percent.
Inhaled THC produces effects within minutes, while oral ingestion is delayed 30 to 120 minutes and peaks at 2 to 4 hours, which drives the dose-stacking pattern behind most edible overdoses.
First-pass hepatic metabolism converts oral THC to 11-hydroxy-THC, a more potent psychoactive metabolite that explains why edibles feel stronger than equivalent inhaled doses.
Delta-8 THC and other semi-synthetic hemp-derived cannabinoids are sold in unregulated markets with inconsistent purity and residual reaction byproducts.
Only three cannabinoid medications have FDA approval: dronabinol, nabilone and cannabidiol (Epidiolex); no whole-plant cannabis product is FDA-approved.
Last updated: September 2026
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape
Quick Answer: Delta-9-THC is a partial agonist at presynaptic CB1 receptors. Average flower potency has risen from under 4% THC in the early 1990s to roughly 15 to 20% today , with concentrates (wax, shatter, distillate, live resin) commonly 60 to 90% . Inhaled THC acts within minutes ; oral THC is delayed 30 to 120 minutes , peaks at 2 to 4 hours , and is converted by first-pass metabolism to the more potent 11-hydroxy-THC . Only dronabinol, nabilone and cannabidiol (Epidiolex) are FDA-approved cannabinoid medications.
1. Why Potency Matters Clinically
Cannabis use disorder, acute psychosis and cannabinoid hyperemesis syndrome all track with total THC exposure , not with "whether the patient uses cannabis." A patient dabbing concentrate three times daily and a patient smoking one low-potency joint on weekends share a diagnosis label and almost nothing else.
- Product Typical THC Notes
- Illicit flower, early 1990s Under 4% The evidence base most clinicians were trained on
- Contemporary flower About 15 to 20% Dispensary and illicit markets converge here
- Hashish 20 to 40% Compressed resin
- Concentrates (wax, shatter, budder, live resin) 60 to 80% Dabbing delivers a very large bolus
- Distillate and vape cartridges 70 to 90%+ Highest available concentration
- Edibles Dose-labeled in mg A standardized serving is commonly 5 to 10 mg THC; packages often contain 100 mg
- Tinctures Variable Sublingual absorption partially bypasses first pass
Teaching anchor: ask for grams per day and product type , not "how much do you smoke?" A gram of 80% concentrate contains roughly 800 mg of THC — the equivalent of 80 to 160 standardized edible servings.
2. Route Determines Everything About Onset
Route Onset Peak Duration Key clinical issue
Inhaled (smoked or vaporized) Seconds to minutes 15 to 30 minutes 2 to 4 hours Self-titration is possible; bronchial irritation; highest reinforcement
Oral (edible) 30 to 120 minutes 2 to 4 hours 6 to 8+ hours Dose stacking — the patient eats more because "nothing is happening" — is the leading cause of acute cannabis toxicity presentations
- Sublingual / tincture 15 to 45 minutes 1.5 to 3 hours 4 to 8 hours Partial first-pass bypass
- Rectal / topical Variable / minimal systemic — — Topicals do not produce intoxication
- The 11-hydroxy-THC point
Oral THC undergoes hepatic first-pass conversion to 11-hydroxy-THC , which crosses the blood-brain barrier readily and is more psychoactive than delta-9-THC itself. This is why an edible dose that matches an inhaled dose on paper produces a stronger, longer and more dysphoric experience — and why edible-related emergency visits skew toward panic, paranoia and, in older adults, cardiac symptoms.
3. Pharmacokinetics That Drive Drug Testing
THC is highly lipophilic and redistributes to adipose tissue.
Terminal elimination half-life in chronic heavy users is roughly 5 to 13 days .
Urine screening detects the inactive metabolite THC-COOH , which can remain positive for 30 or more days after cessation in daily users, and often 3 to 7 days in occasional users.
A positive urine cannabinoid screen therefore does not establish current impairment. This matters enormously in custody, employment, transplant and pain-agreement contexts, and is a point the APRN is frequently asked to explain.
4. The Unregulated Cannabinoid Market
Product What it is Risk
Delta-8 THC Semi-synthetic, usually converted from hemp-derived CBD using acid catalysis Residual reagents and unidentified byproducts; inconsistent labeling; intoxicating despite being marketed as "legal hemp"
Delta-10, THC-O-acetate, HHC Further semi-synthetic derivatives Even less characterized; THC-O-acetate raised specific inhalation-toxicity concerns
High-dose CBD products Marketed for anxiety, pain, sleep Real drug interactions: CBD inhibits CYP2C19 and CYP3A4 and can raise clobazam, warfarin and tacrolimus levels; hepatotoxicity at high doses
Synthetic cannabinoid receptor agonists (K2, Spice) Full CB1 agonists, structurally unrelated to THC Seizures, acute kidney injury, severe agitation, death; not detected on routine cannabinoid immunoassay
Key distinction for the exam: THC is a partial CB1 agonist, which is why fatal overdose from cannabis itself is not described. Synthetic cannabinoid receptor agonists are full agonists with far greater efficacy, which is why they cause seizures, renal failure and deaths.
5. FDA-Approved Cannabinoid Medications
Drug Composition Indication Schedule
Dronabinol (Marinol, Syndros) Synthetic delta-9-THC Chemotherapy-induced nausea and vomiting; AIDS-related anorexia Schedule III (capsules); Syndros solution Schedule II
Nabilone (Cesamet) Synthetic THC analogue Chemotherapy-induced nausea and vomiting Schedule II
Cannabidiol (Epidiolex) Plant-derived purified CBD Lennox-Gastaut, Dravet syndrome, tuberous sclerosis complex Descheduled
No whole-plant or dispensary cannabis product is FDA-approved for any indication. When a patient says "my cannabis is medical," the accurate framing is that it is state-authorized , not FDA-approved, and has not undergone the potency, purity and efficacy review that applies to prescription drugs.